Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000648015 | SCV000769825 | likely benign | Qualitative or quantitative defects of dysferlin | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002222581 | SCV002500221 | uncertain significance | not specified | 2022-03-08 | criteria provided, single submitter | clinical testing | Variant summary: DYSF c.5492C>T (p.Thr1831Met) results in a non-conservative amino acid change located in one of the C2 domains (IPR000008) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 7e-05 in 244432 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in DYSF causing Limb-Girdle Muscular Dystrophy, Autosomal Recessive (7e-05 vs 0.0031), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.5492C>T in individuals affected with Limb-Girdle Muscular Dystrophy, Autosomal Recessive and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and both of them classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Revvity Omics, |
RCV003144430 | SCV003831327 | uncertain significance | not provided | 2021-11-29 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276864 | SCV001463479 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2019-10-28 | no assertion criteria provided | clinical testing |